CCR2+ non-classical monocyte cell populations (Figure 2e) were also comparable in controls [0.60% (0.42–1.31)] and ischemic stroke patients [0.78% (0.52–1.19), U = 75, p = 0.46], as were CCR2+ intermediate monocyte cell populations (Figure 2f) [Ctl: 51.2% (43.8–57.6) and IS: 54.2% (49.0–62.4), U = 65, p = 0.24]. This evidence concerns the gene CCR2 and ischemic stroke.